Zeta AMACR Antibody. Zeta Corporation’s rabbit recombinant monoclonal antibody recognizes AMACR (P504S), an essential enzyme in the b-oxidation of branched-chain fatty acids. Recently, AMACR (P504S) was identified through cDNA library subtraction and microarrays in malignant prostate tissues. High expression of AMACR (P504S) protein is found in prostate adenocarcinoma but not in benign prostate tissue by immunohistochemical staining in paraffin-embedded tissues. The expression of AMACR (P504S) is also detected in two premalignant lesions of the prostate: high-grade prostatic intraepithelial neoplasia (PIN) and atypical adenomatous hyperplasia. Using AMACR (P504S) as a positive marker along with basal cell staining (34bE12 or P63) as a negative marker could help to confirm the diagnosis of small focus of prostate carcinoma on needle biopsy. Zeta’s AMACR antibody provides superior results as a marker for adenocarcinoma as well as early detection of forms of prostate cancer.
Zeta Corporation is a leader in recombinant monoclonal IVD antibodies for immunohistochemistry (IHC) offering 400+ tumor and tissue specific relevant products developed by a pathologist for pathologists. Visit Precision Recombinant Antibodies – IVD Antibodies – About Zeta Corporation (zeta-corp.com) to learn more about Zeta Corporation.